Kira Biotech

Company Announcements:
(reported by the Company)
No items found
Elevator Pitch:

Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders. Its lead candidate, KB312, is a first-in-class, selective, immune-cell depleting monoclonal antibody which targets activated immune cells and aims to restore homeostasis through induction of immune tolerance. Kira Biotech has attracted venture capital funding and is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by well-known US-based rheumatologist and immunologist, Dr Dan Baker.

Category: Health & biotech
Operational Status: Active
ASX Listing Code (if applicable):
Year of Commencement: 2019

The Precinct, Level 2, 315 Brunswick St, Fortitude Valley, QLD 4006, AU

State: Queensland
Overseas Operations: No
Key Personnel:
Awards won: